By Daniel Diaz-Gil, MD· April 2026 · 15 min read
Neonatal jaundice occurs in approximately 60% of term and 80% of preterm infants. While most cases represent benign physiologic jaundice, severe hyperbilirubinemia can lead to bilirubin-induced neurologic dysfunction, including acute bilirubin encephalopathy and kernicterus. The 2022 AAP guideline revision provides updated, evidence-based thresholds for phototherapy and exchange transfusion based on gestational age and neurotoxicity risk factors.
Physiologic jaundice results from normal neonatal physiology: increased red blood cell breakdown, immature hepatic conjugation (only 1% of adult enzyme activity), increased enterohepatic circulation, and low fluid intake in the first days of life. It typically peaks at day 3-5 in term infants and day 5-7 in preterm infants, then gradually resolves.
Pathologic jaundice is suggested by:
Causes of pathologic jaundice include hemolytic disease (ABO/Rh incompatibility, G6PD deficiency), sepsis, cephalohematoma or significant bruising, cholestasis, and metabolic disorders.
The 2022 AAP guidelines explicitly define hyperbilirubinemia neurotoxicity risk factors that lower treatment thresholds:
Low serum albumin increases neurotoxicity risk because of greater availability of unbound bilirubin, the fraction that can cross the blood-brain barrier. Although most laboratories cannot directly measure unbound bilirubin, albumin <3.0 g/dL is considered a neurotoxicity risk factor.
The 2022 AAP guidelines raised phototherapy thresholds for low-risk term infants based on evidence that bilirubin neurotoxicity does not occur until concentrations well above the 2004 exchange transfusion thresholds. Thresholds are determined using hour-specific nomograms based on gestational age and the presence of neurotoxicity risk factors.
Two separate nomograms are used:
Infants <24 hours old with TSB at or above the phototherapy threshold are likely to have a hemolytic process and should be evaluated for hemolytic disease.
Use the AAP Bilirubin 2022 calculator to look up hour-specific phototherapy thresholds, and the Phototherapy Thresholds calculator for a quick reference.
Intensive phototherapy is defined as narrow-spectrum LED blue light (460-490 nm wavelength, peak ~475 nm) with irradiance ≥30 µW/cm²/nm, applied to as much of the infant's surface area as possible. The goal is to decrease the likelihood of further TSB increases that would require escalation of care, including exchange transfusion.
For infants who have already been discharged and develop TSB above the phototherapy threshold, home phototherapy is an option if all of the following criteria are met:
Home phototherapy can be less costly and disruptive to family routines and breastfeeding compared with readmission. However, it should not be used if there are concerns about device quality, family ability to use the device, or ability to measure bilirubin daily.
TSB should be measured to verify efficacy after starting phototherapy. Timing depends on the TSB trajectory (rate of rise) and infant age. For hospitalized infants, bilirubin is typically checked every 12-24 hours during phototherapy, more frequently if TSB is rising rapidly or approaching escalation-of-care thresholds.
Feeding should be maintained during phototherapy to promote bilirubin clearance and avoid dehydration. Interrupting phototherapy for breastfeeding does not impact overall effectiveness if phototherapy is otherwise appropriately used.
Phototherapy may be discontinued when TSB has decreased by at least 2 mg/dL below the hour-specific threshold at which phototherapy was initiated. A longer period of phototherapy should be considered if risk factors for rebound hyperbilirubinemia are present (gestational age <38 weeks, age <48 hours at phototherapy start, hemolytic disease).
Rebound hyperbilirubinemia is defined as TSB reaching the phototherapy threshold within 72-96 hours of discontinuing phototherapy. The overall risk varies from 4.6% to 24% across studies, depending on the prevalence of risk factors. Infants who receive phototherapy during the birth hospitalization are much more likely to experience rebound than those whose first treatment occurs on readmission.
Follow-up after phototherapy is based on rebound risk:
Escalation of care is defined as TSB reaching a level 2 mg/dL below the exchange transfusion threshold. This is a medical emergency requiring:
Exchange transfusion thresholds are substantially higher than phototherapy thresholds and are based on gestational age and neurotoxicity risk factors using separate nomograms (AAP Figure 5 and Figure 6). Use the Exchange Transfusion calculator to check the appropriate threshold.
Urgent exchange transfusion is indicated for:
Intravenous immune globulin (IVIG) 0.5-1 g/kg over 2 hours may be considered for infants with isoimmune hemolytic disease (positive DAT) whose TSB reaches the escalation-of-care threshold. However, effectiveness is unclear, and observational studies suggest an association with necrotizing enterocolitis.
The bilirubin-to-albumin ratio (B/A ratio) can be used in conjunction with TSB to determine the need for exchange transfusion. The ratio is calculated as TSB (mg/dL) divided by serum albumin (g/dL). Use the Bilirubin-Albumin Ratio calculator for this assessment.
Exchange transfusion may be considered if the B/A ratio is:
Recent studies demonstrate that the B/A ratio shows a strong linear association with unbound bilirubin, the biologically relevant fraction associated with neurotoxicity. A 2026 study of 2,248 samples found that B/A ratio = 4.0 identified high unbound bilirubin (≥0.8 µg/dL) with excellent discrimination (sensitivity 0.94, specificity 0.85, AUC 0.95). While the B/A ratio does not allow precise quantification of unbound bilirubin, it serves as a practical screening tool when direct unbound bilirubin measurement is unavailable.
The original 1999 Bhutani nomogram stratified newborns into risk zones based on hour-specific TSB percentiles. A 2021 updated nomogram based on 140 times the number of subjects provides more robust data, particularly in the first 12 hours after birth (which was not included in the 1999 version).
The Bhutani Nomogram calculator plots TSB against hours of life to determine risk zone classification.
The 2022 AAP guidelines recommend using the difference between the bilirubin concentration and the phototherapy threshold at the time of measurement to determine postdischarge follow-up intervals, rather than relying solely on percentile-based risk zones. This approach incorporates gestational age and neurotoxicity risk factors into decision-making.
For breastfed infants still jaundiced at 3-4 weeks of age, and for formula-fed infants still jaundiced at 2 weeks of age, total and direct-reacting (or conjugated) bilirubin should be measured to identify possible pathologic cholestasis.
Conjugated hyperbilirubinemia is defined as direct bilirubin >1.0 mg/dL (if TSB ≤5.0 mg/dL) or >20% of TSB (if TSB >5.0 mg/dL). Causes include biliary atresia, urinary tract infection, isoimmune hemolytic disease, sepsis, and inborn errors of metabolism. Early recognition is essential, as some causes (e.g., biliary atresia) require timely intervention to prevent irreversible liver damage.
Beginning at least 12 hours after birth, if discharge is being considered, the difference between the bilirubin concentration measured closest to discharge and the phototherapy threshold at the time of measurement should be calculated and used to guide follow-up timing.
Predischarge bilirubin screening (TSB or transcutaneous bilirubin) should be performed on all infants. The timing of postdischarge follow-up should consider:
Missing the diagnosis of pathologic jaundice or delaying treatment of severe hyperbilirubinemia can result in permanent neurologic sequelae, including kernicterus.